Climent Elisenda, Benaiges David, Pedro-Botet Juan
Department of Endocrinology and Nutrition, Hospital del Mar, Paseo Marítimo, 25-29, E-08003 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Campus Universitari Mar, Dr. Aiguader, 80, E-08003 Barcelona, Spain.
Department of Endocrinology and Nutrition, Hospital del Mar, Paseo Marítimo, 25-29, E-08003 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Campus Universitari Mar, Dr. Aiguader, 80, E-08003 Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Dr. Aiguader, 80, E-08003 Barcelona, Spain.
Clin Investig Arterioscler. 2019 Sep-Oct;31(5):228-232. doi: 10.1016/j.arteri.2018.12.001. Epub 2019 Feb 5.
Statins have been associated with an increased risk of new-onset diabetes mellitus (NODM), as confirmed in previous observational studies and meta-analyses. Controversy exists as to whether this risk varies depending on statin type or dose. However, there appears to be unanimity regarding the different associated factors that raise this risk. Furthermore, diverse pathophysiologic mechanisms have been described that could explain the increased risk of diabetes in patients with statin treatment. These fundamentally cause a rise in insulin resistance together with a decrease in insulin secretion. The present review aimed to describe the relationship between statin treatment and the presence of diabetes and provide an update of previous published evidence and the possible mechanisms involved.
正如先前的观察性研究和荟萃分析所证实的那样，他汀类药物与新发糖尿病（NODM）风险增加有关。关于这种风险是否因他汀类药物类型或剂量而异，目前仍存在争议。然而，对于增加这种风险的不同相关因素，似乎已达成共识。此外，已经描述了多种病理生理机制，这些机制可以解释接受他汀类药物治疗的患者患糖尿病风险增加的原因。这些机制从根本上导致胰岛素抵抗增加以及胰岛素分泌减少。本综述旨在描述他汀类药物治疗与糖尿病发生之间的关系，并更新先前发表的证据以及可能涉及的机制。
